Cancer & SURVIVEiT News
Category Filter:
FDA approves Opdualag for unresectable or metastatic melanoma
FDA approves Opdualag for unresectable or metastatic melanoma On March 18, 2022, the Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients…
FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma
FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma On January 25, 2022, the Food and Drug Administration approved tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell…
FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma
FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma On July 30, 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib…
Immunotherapy Cancer Patient Story: Keeping a Positive Outlook When Melanoma Returned
During Cancer Immunotherapy Awareness Month, we want to share cancer patient stories and how they came to find immunotherapy as a treatment option. See how Summer’s positive outlook and support…
6 Warning Signs of Melanoma
Early detection is crucial when it comes to finding melanoma. In fact, according to the Skin Cancer Foundation, there is a 99% 5-year survival rate for patients in the U.S.…
Big News for BRAF-Mutant Melanoma Patients
An international trial was conducted that studied patients with previously untreated advanced BRAF-mutant melanoma to the doublet or triplet regimens. Here is an overview of the results. Triplet Succeeds in…
FDA approves first treatment for advanced form of the second most common skin cancer
FDA approves first treatment for advanced form of the second most common skin cancer New drug targets PD-1 pathway The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection…